Welcome to our dedicated page for ABEONA THERAPEUTICS SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abeona Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed commercial-stage biopharmaceutical company with common stock traded as ABEO. Recent Form 8-K reports cover operating results, ZEVASKYN commercial launch disclosures, completion of the sale of a Rare Pediatric Disease Priority Review Voucher received after FDA approval of ZEVASKYN, and other material events.
Proxy and governance filings describe annual meeting procedures, board composition, committee assignments, director independence, compensation matters, and amendments to the company’s bylaws. Those bylaws disclosures address stockholder meeting mechanics, virtual meetings, proposal and nomination procedures, quorum requirements, and other Delaware corporate governance provisions.
Abeona Therapeutics insider Mark Alvino filed a notice of proposed sale of 2,000 shares of common stock. The shares are planned to be sold through Stifel Nicolaus & Company on Nasdaq around 02/02/2026, with an aggregate market value of $10,180.00.
The 2,000 shares were acquired on 01/31/2026 as restricted stock units granted by the issuer as equity compensation. Over the past three months, Alvino has already sold 15,000 and 13,500 common shares, generating gross proceeds of $71,168.00 and $70,574.00, respectively.
Abeona Therapeutics shareholder filed a notice of proposed sale under Rule 144 for 18,065 shares of common stock through Stifel Nicolaus & Company on 02/02/2026 on Nasdaq. The filing lists an aggregate market value of $91,962.00 for these shares and notes that 54,191,361 shares of common stock were outstanding.
The seller acquired 36,101 shares of common stock on 01/31/2026 via restricted stock units granted as equity compensation from the issuer, with payment also dated 01/31/2026. The form states the signer represents they are not aware of undisclosed material adverse information about Abeona’s current or prospective operations.
Abeona Therapeutics director Leila Alland reported selling 18,065 shares of common stock on February 2, 2026 at a weighted average price of $5.0906 per share. The sale was made to cover tax obligations from the vesting of restricted stock awards, and she now beneficially owns 173,614 shares directly.
Abeona Therapeutics director Mark Alvino reported a small share sale to cover taxes. On February 2, 2026, he sold 2,000 shares of common stock in Abeona Therapeutics at a weighted average price of $5.0906 per share.
The filing explains that the sale was made to satisfy tax obligations arising from the vesting of restricted stock awards, rather than as a discretionary portfolio decision. After this transaction, Alvino directly beneficially owned 84,065 shares of Abeona Therapeutics common stock, and no derivative securities were reported.
Abeona Therapeutics director Donald A. Wuchterl reported receiving 37,313 shares of common stock as restricted stock on January 26, 2026, at a price of $0.00 per share. After this grant, he directly holds 182,749 shares of Abeona common stock.
According to the filing, all of this restricted stock will vest on January 26, 2027, meaning the shares become fully owned by him on that date if the vesting conditions are met.
Abeona Therapeutics Inc. director Bernhardt G. Zeiher received a grant of 37,313 shares of common stock on January 26, 2026. The shares were awarded at a price of $0.00 per share as restricted stock. After this grant, he directly holds 84,458 shares. All of the restricted stock will vest on January 26, 2027, meaning the award becomes fully owned on that date if conditions are met.
Abeona Therapeutics director Eric Crombez received a new equity grant. On January 26, 2026, he was awarded 37,313 shares of Abeona Therapeutics common stock as restricted stock at a price of $0.00 per share. After this grant, he directly owns 79,740 common shares.
The filing states that all of this restricted stock will vest on January 26, 2027, meaning the shares become fully earned on that date if vesting conditions are satisfied.
Abeona Therapeutics director receives restricted stock grant. Director Christine Silverstein Berni was awarded 37,313 shares of Abeona Therapeutics common stock on January 26, 2026 at a price of $0.00 per share. All of this restricted stock will vest on January 26, 2027.
Following this grant, she beneficially owns 157,792 shares of Abeona Therapeutics common stock in direct ownership.
Abeona Therapeutics director Michael Amoroso received a stock grant. On January 26, 2026, he was awarded 37,313 shares of Abeona Therapeutics common stock at a price of $0.00 per share as restricted stock. After this grant, he beneficially owned 217,779 shares directly. All of the restricted stock is scheduled to vest on January 26, 2027.
Abeona Therapeutics director Faith L. Charles received an equity grant of 37,313 shares of common stock as restricted stock on January 26, 2026. The award was reported at a price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase.
Following this grant, Charles beneficially owns 176,407 shares of Abeona common stock in direct form. All of the restricted stock from this award is scheduled to vest on January 26, 2027, aligning her compensation with the company’s future performance over the vesting period.